ClinicalTrials.gg
CompletedNCT00822172ECLECTICUpdated Nov 29, 2019Results posted

Evaluation of Cilostazol in Combination With L-Carnitine

A Phase 4 interventional study of Levocarnitine tartrate and cilostazol in Peripheral Vascular Disease, Intermittent Claudication and Peripheral Arterial Disease, sponsored by Colorado Prevention Center. Completed at 24 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2019-11-29.

Primary conditionIntermittent ClaudicationRegistry: Peripheral Vascular DiseasesReclassifiedWhy we changed it
Registry
Peripheral Vascular Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Intermittent Claudication
Why
  1. The study's listed conditions name Intermittent Claudication, a narrower term within Peripheral Vascular Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Colorado Prevention Center · Phase 4, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
164
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 119 studies in Intermittent Claudication with a site in United States — 14 open to participants now, 17 under way, 2 of them phase 3. Intermittent Claudication · United States.

Enrollment
29th of 104
164 · median 73
Started
2008
with 5 others
Phase 4
9 of 119
none open now
Registered
39th of 119
by date

Among the 119 studies in Intermittent Claudication with a site in United States, this one is the 29th largest by enrollment of the 104 interventional ones that give a count, is one of 6 that started in 2008, is one of 9 in phase 4, and was the 39th registered.

Intermittent Claudication

309 studies on the registry are indexed under Intermittent Claudication; 46 are open to participants now.

Browse Intermittent Claudication studies →

Open to participants now

14 of the 119 studies in Intermittent Claudication with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 33 Intermittent Claudication studies recruiting now, 21 (64%) set no upper age limit and none (0%) stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 119 studies in Intermittent Claudication with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to see how safe and effective L carnitine taken with cilostazol is compared to placebo taken with cilostazol for people with intermittent claudication. A second purpose of the study is to see if L-carnitine is absorbed into the blood stream.

Read the detailed description

Peripheral Artery Disease (PAD) is a narrowing of the blood vessels that supply the leg with blood. It is caused by atherosclerosis (hardening of the arteries).

Muscles require oxygen carried by the blood. When the leg muscles do not get enough blood and oxygen, this can cause pain, cramping, fatigue, and/or discomfort in the leg muscles during walking or exercise. These symptoms are called intermittent claudication (IC). In more severe cases, tissues do not get enough blood and oxygen at rest, and pain may also be present when the legs are resting. Peripheral Artery Disease (PAD)is one of the most common causes of pain and disability in people between 55 and 75 years of age.

Cilostazol is a medication currently available by prescription for intermittent claudication. L-carnitine is an over-the-counter supplement. It is a natural substance in the human body and is also in some red meats, nuts, and energy drinks.

Some subjects in the study will take L-carnitine with cilostazol and others will take placebo with cilostazol. The purpose of this study is to see how safe and effective L carnitine taken with cilostazol is compared to placebo taken with cilostazol for people with intermittent claudication. A placebo is a tablet or pill that looks like regular medication, but it doesn't have any actual medicine in it. A second purpose of the study is to see if L-carnitine is absorbed into the blood stream.

03

Conditions studied

  • Peripheral Vascular Disease
  • Intermittent Claudication
  • Peripheral Arterial Disease

Keywords

  • Peripheral Vascular Disease
  • Peripheral Arterial Disease
  • Intermittent Claudication
  • Peak Walking Time
  • Claudication Onset Time
  • Cilostazol
  • Carnitine
04

In context

Intermittent Claudication Reclassified

309 studies on the registry are indexed under Intermittent Claudication; 46 are open to participants now.

This study's enrollment of 164 is above the median of 74 across 242 interventional studies indexed under Intermittent Claudication.

Browse Intermittent Claudication studies →

Lead sponsor

Colorado Prevention Center is the lead sponsor of 8 studies on the registry; 4 are open to participants now.

Compared within Intermittent Claudication, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Peripheral Vascular Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject is >40 years old.
  • The subject has a diagnosis of Intermittent Claudication (IC) due to Peripheral Artery Disease (PAD).
  • Ankle brachial index (ABI) \< 0.90 in at least one extremity, or if Ankle brachial index (ABI)is ≥ 0.90 to ≤ 1.0, a reduction of at least 20% in Ankle brachial index (ABI), in at least one extremity, when measured within 1 minute after claudication-limiting treadmill testing. If the subject has non-compressible arteries then a toe brachial index (TBI) \< 0.70 is required in at least one extremity.
  • Symptoms of Intermittent Claudication (IC)must be stable for at least 3 months prior to Screening 1.
  • Peak Walking Time (PWT) of ≥ 1 to ≤ 12 minutes on a Gardner protocol at Screening 2.
  • If the subject is currently on statin therapy, they need to have been on statin therapy for at least 3 months prior to Screening 1. Subjects who have recently discontinued statin therapy must "wash-out" for at least one month prior to Screening 1.
  • Tolerance to background therapy of cilostazol (approximately 2 weeks of 50 mg by mouth (PO) twice daily (BID), approximately 1 week of 100 mg PO BID) between Screening 2 and Baseline Visit.
  • Subjects must be either male or females that are , surgically incapable of bearing children or if they are of must have a negative serum pregnancy test at Screening 1 and a negative urine pregnancy test at Day 0 and must agree to use double-barrier methods until the end of therapy (Day 180 Visit).
  • The subject is able to comply with scheduled visits, treatment plan and laboratory tests.
  • The subject is willing to participate in this study as documented by written .
  • During the tolerance phase of the Screening period, the subject demonstrates at least 70% compliance with cilostazol and is willing to continue treatment.

Exclusion criteria

Exclusion Criteria:

  • Evidence of critical limb ischemia (CLI) (e.g., ischemic rest pain or ischemic ulceration).
  • The subject has had a major amputation of the leg or any other amputation that limits walking ability.
  • The subject has diabetes mellitus type 1 or poorly controlled diabetes mellitus type 2 ( (HbA1c) > 10).
  • The subject has had a (TIA) or deep vein thrombosis in the last 3 months.
  • The subject has had a stroke within the last 6 months.
  • The subject has participated in an angiogenic gene therapy study, unless known to be given placebo.
  • The subject has any of the following laboratory parameters at Screening 1:

    • (ALT), aspartate aminotransferase (AST) or total >3 times the (ULN)
    • Serum creatinine >2.5 mg/dL
    • (Hb) \<10 g/dL
    • White blood cell (WBC) count \<3.0 x 103/µL; or > 15 x 103/µL
    • count \<100 x 103/µL
  • The subject walks less than 1 minute at 2 miles per hour (mph), 0% grade as determined during the Screening 1 treadmill familiarization.
  • The subject has (ECG) abnormalities at rest or changes during exercise or post-exercise at Screening 2 or Day 0.
  • The subject has any history or clinical evidence of congestive heart failure (CHF), with which the clinician-investigator concurs.
  • The subject has uncontrolled hypertension (resting blood pressure (BP) > 180/100 mmHg) or uncontrolled arrhythmic disorders at Screening 1.
  • History of coronary or peripheral revascularization within 6 months prior to Screening 1.
  • The subject plans to undergo coronary or peripheral revascularization during the course of the study.
  • The subject is currently taking L-carnitine or medication for claudication (including pentoxifylline or cilostazol). In this situation, the subject would become eligible for Screening 1 after a 6 week washout of the medication.
  • Subjects currently taking or those who anticipate taking ketoconazole, itraconazole, or erythromycin. The subject would become eligible for Screening 1 immediately after completion of therapy or discontinuation of the drug(s).
  • The subject has a known, active that requires active anti-neoplastic therapy. (stable basal cell skin cancer allowed. Cancer being treated soley with hormonal therapy is allowed.)
  • The subject has a severe co-morbidity with an expected survival of less than 2 years.
  • The subject's Peak Walking Time (PWT) is limited by symptoms other than claudication (e.g., shortness of breath (SOB), fatigue, angina, arthritis, etc.). If, in the opinion of the investigator, the subject were to improve their Peak Walking Time (PWT) from study therapy to the extent that his or her walking would then be limited by a symptom other than claudication, the subject should not be enrolled.
  • The subject has a history of alcohol or other substance abuse within 6 months of Screening 1.
  • The subject has an inability to tolerate oral medication administration.
  • The subject has a known or suspected allergy to the study medication(s) or class of study medication(s) (cilostazol or L-carnitine) to be administered.
  • The subject has initiated an exercise training program within 3 months of Screening 1, has the inability to maintain his or her current level of physical activity throughout the study, or the subject plans on enrolling in an exercise training program during the study.
  • The subject plans to change his/her smoking status during the planned duration of this study (subjects will be advised that stopping smoking is best for his/her health).
  • The subject is currently pregnant or breastfeeding.
  • The subject has received an drug or biological agent within 30 days prior to Screening 1.
  • The subject is currently participating in or plans to enroll in another clinical trial during this study.
  • The subject has any other clinically significant medical or psychiatric condition that in the opinion of the Investigator could impact the subject's ability to successfully complete this trial.
  • In the Investigator's opinion, the subject experienced any Adverse Events (AEs) during the tolerance phase of the Screening period that present a potential ongoing safety concern.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
164 participants (actual)

Study arms

  • Active comparator
    Cilostazol + L-Carnitine

    1 tablet cilostazol 100 mg PO BID and 3 capsules L-carnitine 334 mg PO BID

    Dietary Supplement: Levocarnitine tartrate · Drug: cilostazol

  • Placebo comparator
    Cilostazol + Placebo

    1 tablet cilostazol 100 mg PO BID and 3 capsules placebo PO BID

    Drug: cilostazol

Interventions

  • Dietary supplementLevocarnitine tartrate

    Capsule form, 1,002 mg (3 capsules) taken by mouth two times per day (morning and evening). L-carnitine will be taken from Day 0 to Day 180.

    Also known as: Carnitine, L-carnitine, Levocarnitine

  • Background therapy beginning at 50mg (1 pill) taken by mouth two times per day for two to three weeks. Then 100 mg (1 pill) to be taken by mouth two times per day (morning and evening) for one to two weeks. Randomized therapy will consist of 100 mg (1 pill) to be taken by mouth two times per day (morning and evening) for approximately 180 days.

    Also known as: Pletal

07

What researchers measure

Primary outcomes

  1. Change From Baseline in Peak Walking Time (PWT) at Day 180

    Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed.

    Time frame: Baseline, Day 180

Secondary outcomes

  1. Change From Baseline in Peak Walking Time at Day 180

    Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed.

    Time frame: Baseline, Day 180

  2. Change From Baseline in Peak Walking Time at Day 90

    Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed.

    Time frame: Baseline, Day 90

  3. Change From Baseline in Claudication Onset Time at Day 180

    Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed.

    Time frame: Baseline, Day 180

  4. Change From Baseline in Claudication Onset Time at Day 90

    Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed.

    Time frame: Baseline, Day 90

  5. Change From Baseline in Walking Impairment Questionnaire for Walking Distance at Day 180

    Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment

    Time frame: Baseline, Day 180

  6. Change From Baseline in Walking Impairment Questionnaire for Walking Distance at Day 90

    Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment

    Time frame: Baseline, Day 90

08

Results

Posted May 22, 2013

Participant flow

The first participant was randomized on September 19th, 2008 and the last subject was randomized on May 7, 2010. Clinical study sites were a mixture of university/hospital settings, Veteran Affairs hospitals, professional research centers and medical clinics.

Participant flow — Overall Study
MilestoneCilostazol + L-CarnitineCilostazol + Placebo
Started8083
Completed6564
Not completed1519
Withdrew: Adverse event1012
Withdrew: Death10
Withdrew: Lost to follow-up31
Withdrew: Withdrawal by subject14
Withdrew: Site closed01
Withdrew: Other01

Outcome measures

PrimaryChange From Baseline in Peak Walking Time (PWT) at Day 180

Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed.

Time frame:
Baseline, Day 180
Reported as:
Mean · Log Minutes
Change From Baseline in Peak Walking Time (PWT) at Day 180
Log MinutesCilostazol + L-CarnitineCilostazol + Placebo
Change From Baseline in Peak Walking Time (PWT) at Day 1800.241 ± 0.38360.134 ± 0.3343
Statistical analysis
  • Cilostazol + L-Carnitine vs Cilostazol + Placebo · two-sample equal-variances t-test · p = 0.076
SecondaryChange From Baseline in Peak Walking Time at Day 180

Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed.

Time frame:
Baseline, Day 180
Reported as:
Mean · Log Minutes
Change From Baseline in Peak Walking Time at Day 180
Log MinutesCilostazol + L-CarnitineCilostazol + Placebo
Change From Baseline in Peak Walking Time at Day 1800.267 ± 0.35160.145 ± 0.3124
Statistical analysis
  • Cilostazol + L-Carnitine vs Cilostazol + Placebo · two-sample equal-variances t-test · p = 0.048
SecondaryChange From Baseline in Peak Walking Time at Day 90

Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed.

Time frame:
Baseline, Day 90
Reported as:
Mean · Log Minutes
Change From Baseline in Peak Walking Time at Day 90
Log MinutesCilostazol + L-CarnitineCilostazol + Placebo
Change From Baseline in Peak Walking Time at Day 900.166 ± 0.35710.139 ± 0.3293
Statistical analysis
  • Cilostazol + L-Carnitine vs Cilostazol + Placebo · two-sample equal-variances t-test · p = 0.650
SecondaryChange From Baseline in Claudication Onset Time at Day 180

Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed.

Time frame:
Baseline, Day 180
Reported as:
Mean · Log Minutes
Change From Baseline in Claudication Onset Time at Day 180
Log MinutesCilostazol + L-CarnitineCilostazol + Placebo
Change From Baseline in Claudication Onset Time at Day 1801.065 ± 0.66800.896 ± 0.7364
SecondaryChange From Baseline in Claudication Onset Time at Day 90

Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed.

Time frame:
Baseline, Day 90
Reported as:
Mean · Log Minutes
Change From Baseline in Claudication Onset Time at Day 90
Log MinutesCilostazol + L-CarnitineCilostazol + Placebo
Change From Baseline in Claudication Onset Time at Day 901.001 ± 0.64760.815 ± 0.7000
SecondaryChange From Baseline in Walking Impairment Questionnaire for Walking Distance at Day 180

Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment

Time frame:
Baseline, Day 180
Reported as:
Mean · score on a scale
Change From Baseline in Walking Impairment Questionnaire for Walking Distance at Day 180
score on a scaleCilostazol + L-CarnitineCilostazol + Placebo
Change From Baseline in Walking Impairment Questionnaire for Walking Distance at Day 18013.20 ± 22.0016.57 ± 24.288
SecondaryChange From Baseline in Walking Impairment Questionnaire for Walking Distance at Day 90

Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment

Time frame:
Baseline, Day 90
Reported as:
Mean · score on a scale
Change From Baseline in Walking Impairment Questionnaire for Walking Distance at Day 90
score on a scaleCilostazol + L-CarnitineCilostazol + Placebo
Change From Baseline in Walking Impairment Questionnaire for Walking Distance at Day 9012.98 ± 25.25110.01 ± 21.354

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cilostazol + L-Carnitine—11/80 (13.8%)19/80 (23.8%)
Cilostazol + Placebo—10/83 (12%)22/83 (26.5%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventCilostazol + L-CarnitineCilostazol + Placebo
Abdominal herniaGeneral disorders2/800/83
Myocardial infarctionCardiac disorders2/800/83
Coronary artery diseaseCardiac disorders1/801/83
Ureteric fistulaRenal and urinary disorders1/800/83
Cervicobrachial syndromeMusculoskeletal and connective tissue disorders1/800/83
CellulitisMusculoskeletal and connective tissue disorders1/800/83
Pancreatitis acuteEndocrine disorders1/800/83
Back painMusculoskeletal and connective tissue disorders1/800/83
Sick sinus syndromeCardiac disorders1/800/83
Prostate cancerRenal and urinary disorders0/801/83
Most frequent other events
Most frequent other events
EventCilostazol + L-CarnitineCilostazol + Placebo
HeadacheNervous system disorders10/8014/83
DiarrhoeaGastrointestinal disorders9/808/83

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cilostazol + L-CarnitineCilostazol + PlaceboTotal
<=18 years000
Between 18 and 65 years432770
>=65 years375693
Age, Continuous
Age, Continuous(years)Cilostazol + L-CarnitineCilostazol + PlaceboTotal
Mean65.8 ± 9.3967.3 ± 8.0066.5 ± 8.74
Sex: Female, Male
Sex: Female, Male(Participants)Cilostazol + L-CarnitineCilostazol + PlaceboTotal
Female141630
Male6667133
Region of Enrollment
Region of Enrollment(participants)Cilostazol + L-CarnitineCilostazol + PlaceboTotal
United States8083163
09

Study locations

24 sites
  • Internal Medicine Physicians Associates
    Phoenix, Arizona 85006, United States
  • Tatum Ridge Internal Medicine
    Phoenix, Arizona 85032, United States
  • Central Arkansas Veteran's Healthcare System
    Little Rock, Arkansas 72205, United States
  • VA Palo Alto Health Care System
    Palo Alto, California 94304, United States
  • University of California at Davis Vascular Center
    Sacramento, California 95817, United States
  • Sacramento Heart and Vascular Research Center
    Sacramento, California 95825, United States
  • Apex Research Institute
    Santa Ana, California 92705, United States
  • Aurora Denver Cardiology Associates
    Aurora, Colorado 80012, United States
  • Aurora Denver Cardiology Associates
    Denver, Colorado 80218, United States
  • Pensacola Research Consultants, Inc.
    Pensacola, Florida 32504, United States
  • DMI Healthcare Group, Inc.
    Pinellas Park, Florida 33782, United States
  • Meridian Research
    Saint Petersburg, Florida 33709, United States
  • Ochsner Medical Center
    New Orleans, Louisiana 70121, United States
  • HPV Heart, PA
    Columbia, Maryland 21044, United States
  • University of Massachusetts Medical Center
    Worcester, Massachusetts 01605, United States
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • University of Rochester Medical Center
    Rochester, New York 14623, United States
  • Durham VA-Medical Center
    Durham, North Carolina 27705, United States
  • Radiant Research, Inc
    Columbus, Ohio 43212, United States
  • Jobst Vascular Center
    Toledo, Ohio 43606, United States
  • Peripheral Vascular Associates
    San Antonio, Texas 78205, United States
  • Clinical Trials of Texas, Inc.
    San Antonio, Texas 78229, United States
  • Radiant Research- Salt Lake City
    Salt Lake City, Utah 84107, United States
  • Beloit Clinic Research Office
    Beloit, Wisconsin 53511, United States
10

References and documents

Publications

  • Hiatt WR. Carnitine and peripheral arterial disease. Ann N Y Acad Sci. 2004 Nov;1033:92-8. doi: 10.1196/annals.1320.008. PubMed 15591006 ↗
  • Hiatt WR, Nawaz D, Brass EP. Carnitine metabolism during exercise in patients with peripheral vascular disease. J Appl Physiol (1985). 1987 Jun;62(6):2383-7. doi: 10.1152/jappl.1987.62.6.2383. PubMed 3610932 ↗
  • Hiatt WR. Management of Intermittent Claudication. Contemporary Diagnosis and management of Peripheral arterial Disease. 1 ed. Newtown: Handvbooks in Healthcare Co., Inc., 2004:51-9
  • Rowlands TE, Donnelly R. Medical therapy for intermittent claudication. Eur J Vasc Endovasc Surg. 2007 Sep;34(3):314-21. doi: 10.1016/j.ejvs.2007.04.001. Epub 2007 May 29. PubMed 17532651 ↗
  • Dawson DL, Cutler BS, Meissner MH, Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation. 1998 Aug 18;98(7):678-86. doi: 10.1161/01.cir.98.7.678. PubMed 9715861 ↗
  • Money SR, Herd JA, Isaacsohn JL, Davidson M, Cutler B, Heckman J, Forbes WP. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg. 1998 Feb;27(2):267-74; discussion 274-5. doi: 10.1016/s0741-5214(98)70357-x. PubMed 9510281 ↗
  • Elam MB, Heckman J, Crouse JR, Hunninghake DB, Herd JA, Davidson M, Gordon IL, Bortey EB, Forbes WP. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol. 1998 Dec;18(12):1942-7. doi: 10.1161/01.atv.18.12.1942. PubMed 9848888 ↗
  • Beebe HG, Dawson DL, Cutler BS, Herd JA, Strandness DE Jr, Bortey EB, Forbes WP. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med. 1999 Sep 27;159(17):2041-50. doi: 10.1001/archinte.159.17.2041. PubMed 10510990 ↗
  • Dawson DL, Cutler BS, Hiatt WR, Hobson RW 2nd, Martin JD, Bortey EB, Forbes WP, Strandness DE Jr. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med. 2000 Nov;109(7):523-30. doi: 10.1016/s0002-9343(00)00569-6. PubMed 11063952 ↗
  • Strandness DE Jr, Dalman RL, Panian S, Rendell MS, Comp PC, Zhang P, Forbes WP. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vasc Endovascular Surg. 2002 Mar-Apr;36(2):83-91. doi: 10.1177/153857440203600202. PubMed 11951094 ↗
  • Regensteiner JG, Ware JE Jr, McCarthy WJ, Zhang P, Forbes WP, Heckman J, Hiatt WR. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. J Am Geriatr Soc. 2002 Dec;50(12):1939-46. doi: 10.1046/j.1532-5415.2002.50604.x. PubMed 12473004 ↗
  • Thompson PD, Zimet R, Forbes WP, Zhang P. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol. 2002 Dec 15;90(12):1314-9. doi: 10.1016/s0002-9149(02)02869-2. PubMed 12480040 ↗
  • Pratt CM. Analysis of the cilostazol safety database. Am J Cardiol. 2001 Jun 28;87(12A):28D-33D. doi: 10.1016/s0002-9149(01)01719-2. PubMed 11434897 ↗
  • Hiatt WR, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). J Vasc Surg. 2008 Feb;47(2):330-336. doi: 10.1016/j.jvs.2007.10.009. Epub 2007 Dec 26. PubMed 18155871 ↗
  • Hiatt WR, Regensteiner JG, Creager MA, Hirsch AT, Cooke JP, Olin JW, Gorbunov GN, Isner J, Lukjanov YV, Tsitsiashvili MS, Zabelskaya TF, Amato A. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. Am J Med. 2001 Jun 1;110(8):616-22. doi: 10.1016/s0002-9343(01)00704-5. PubMed 11382369 ↗
  • Muller DM, Seim H, Kiess W, Loster H, Richter T. Effects of oral L-carnitine supplementation on in vivo long-chain fatty acid oxidation in healthy adults. Metabolism. 2002 Nov;51(11):1389-91. doi: 10.1053/meta.2002.35181. PubMed 12404185 ↗
  • Brass EP, Anthony R, Cobb FR, Koda I, Jiao J, Hiatt WR. The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J Am Coll Cardiol. 2006 Dec 19;48(12):2539-45. doi: 10.1016/j.jacc.2006.07.064. Epub 2006 Nov 28. PubMed 17174195 ↗
  • Hiatt WR, Hirsch AT, Regensteiner JG, Brass EP. Clinical trials for claudication. Assessment of exercise performance, functional status, and clinical end points. Vascular Clinical Trialists. Circulation. 1995 Aug 1;92(3):614-21. doi: 10.1161/01.cir.92.3.614. No abstract available. PubMed 7634476 ↗
  • Rizza v, Lorefice R, Rizza N et al. Pharmacokinetics of L-Carnitine in Human Subjects. In: Ferrari R, DiMauro S, Sherwood G, eds. L-Carnitine and its Role in Medicine: From Function to Therapy. 1 ed San Diego: Academic Press, Inc., 1992:63-77.
  • Hiatt WR, Wolfel EE, Regensteiner JG, Brass EP. Skeletal muscle carnitine metabolism in patients with unilateral peripheral arterial disease. J Appl Physiol (1985). 1992 Jul;73(1):346-53. doi: 10.1152/jappl.1992.73.1.346. PubMed 1506390 ↗
  • Brevetti G, Angelini C, Rosa M, Carrozzo R, Perna S, Corsi M, Matarazzo A, Marcialis A. Muscle carnitine deficiency in patients with severe peripheral vascular disease. Circulation. 1991 Oct;84(4):1490-5. doi: 10.1161/01.cir.84.4.1490. PubMed 1914091 ↗
  • Bauer TA, Brass EP, Hiatt WR. Impaired muscle oxygen use at onset of exercise in peripheral arterial disease. J Vasc Surg. 2004 Sep;40(3):488-93. doi: 10.1016/j.jvs.2004.06.025. PubMed 15337878 ↗
  • Bauer TA, Brass EP, Barstow TJ, Hiatt WR. Skeletal muscle StO2 kinetics are slowed during low work rate calf exercise in peripheral arterial disease. Eur J Appl Physiol. 2007 May;100(2):143-51. doi: 10.1007/s00421-007-0412-0. Epub 2007 Feb 20. PubMed 17310391 ↗
  • Brass EP, Hiatt WR, Gardner AW, Hoppel CL. Decreased NADH dehydrogenase and ubiquinol-cytochrome c oxidoreductase in peripheral arterial disease. Am J Physiol Heart Circ Physiol. 2001 Feb;280(2):H603-9. doi: 10.1152/ajpheart.2001.280.2.H603. PubMed 11158957 ↗
  • Brass EP. Supplemental carnitine and exercise. Am J Clin Nutr. 2000 Aug;72(2 Suppl):618S-23S. doi: 10.1093/ajcn/72.2.618S. PubMed 10919968 ↗
  • Hiatt WR, Regensteiner JG, Wolfel EE, Ruff L, Brass EP. Carnitine and acylcarnitine metabolism during exercise in humans. Dependence on skeletal muscle metabolic state. J Clin Invest. 1989 Oct;84(4):1167-73. doi: 10.1172/JCI114281. PubMed 2794054 ↗
  • Eder K, Felgner J, Becker K, Kluge H. Free and total carnitine concentrations in pig plasma after oral ingestion of various L-carnitine compounds. Int J Vitam Nutr Res. 2005 Jan;75(1):3-9. doi: 10.1024/0300-9831.75.1.3. PubMed 15830915 ↗
  • Rubin MR, Volek JS, Gomez AL, Ratamess NA, French DN, Sharman MJ, Kraemer WJ. Safety measures of L-carnitine L-tartrate supplementation in healthy men. J Strength Cond Res. 2001 Nov;15(4):486-90. PubMed 11726261 ↗
  • Giamberardino MA, Dragani L, Valente R, Di Lisa F, Saggini R, Vecchiet L. Effects of prolonged L-carnitine administration on delayed muscle pain and CK release after eccentric effort. Int J Sports Med. 1996 Jul;17(5):320-4. doi: 10.1055/s-2007-972854. PubMed 8858401 ↗
  • Volek JS, Kraemer WJ, Rubin MR, Gomez AL, Ratamess NA, Gaynor P. L-Carnitine L-tartrate supplementation favorably affects markers of recovery from exercise stress. Am J Physiol Endocrinol Metab. 2002 Feb;282(2):E474-82. doi: 10.1152/ajpendo.00277.2001. PubMed 11788381 ↗
  • Kraemer WJ, Volek JS, French DN, Rubin MR, Sharman MJ, Gomez AL, Ratamess NA, Newton RU, Jemiolo B, Craig BW, Hakkinen K. The effects of L-carnitine L-tartrate supplementation on hormonal responses to resistance exercise and recovery. J Strength Cond Res. 2003 Aug;17(3):455-62. doi: 10.1519/1533-4287(2003)0172.0.co;2. PubMed 12930169 ↗
  • Spiering BA, Kraemer WJ, Vingren JL, Hatfield DL, Fragala MS, Ho JY, Maresh CM, Anderson JM, Volek JS. Responses of criterion variables to different supplemental doses of L-carnitine L-tartrate. J Strength Cond Res. 2007 Feb;21(1):259-64. doi: 10.1519/00124278-200702000-00046. PubMed 17313301 ↗
  • Brevetti G, Chiariello M, Ferulano G, Policicchio A, Nevola E, Rossini A, Attisano T, Ambrosio G, Siliprandi N, Angelini C. Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study. Circulation. 1988 Apr;77(4):767-73. doi: 10.1161/01.cir.77.4.767. PubMed 3280157 ↗
  • Brevetti G, Perna S, Sabba C, Rossini A, Scotto di Uccio V, Berardi E, Godi L. Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. Eur Heart J. 1992 Feb;13(2):251-5. doi: 10.1093/oxfordjournals.eurheartj.a060155. PubMed 1555624 ↗
  • Brevetti G, Diehm C, Lambert D. European multicenter study on propionyl-L-carnitine in intermittent claudication. J Am Coll Cardiol. 1999 Nov 1;34(5):1618-24. doi: 10.1016/s0735-1097(99)00373-3. PubMed 10551714 ↗
  • Goldenberg NA, Krantz MJ, Hiatt WR. L-Carnitine plus cilostazol versus cilostazol alone for the treatment of claudication in patients with peripheral artery disease: a multicenter, randomized, double-blind, placebo-controlled trial. Vasc Med. 2012 Jun;17(3):145-54. doi: 10.1177/1358863X12442264. PubMed 22615190 ↗

Related links

11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2008, a primary completion of Nov 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

Results were first posted in May 2013, 2 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2009
First posted
Jan 14, 2009
Start
Sep 2008
Primary completionActual
Nov 2010
CompletionActual
Dec 2010
Results first posted
May 22, 2013
Last update
Nov 29, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00822172
Lead sponsor
Colorado Prevention Center
Responsible party
Sponsor
First posted
Jan 14, 2009
Start date
Sep 2008
Primary completion
Nov 2010
Completion
Dec 2010
Results posted
May 22, 2013
Last update
Nov 29, 2019

Study contacts

Neil Goldenberg, MD, PhD
study chair · University of Colorado Heather Sciences Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion